Predictive ability of partin tables 2001 in a Welsh population

Urologia Internationalis

Volumn 76, Issue 3, 2006, Pages 217-222

  Ayyathurai, Rajinikanth ^a,b   Ananthakrishnan, Krishnan ^a   Rajasundaram, Ramanan ^a   Knight, Ross J ^a   Toussi, Hamid ^a   Srinivasan, Vaikuntam ^a  

^a GLAN CLWYD HOSPITAL   (United Kingdom)

^b PRINCESS OF WALES HOSPITAL   (United Kingdom)

Author keywords

Organ confined disease; Partin table; Prostate; Prostate cancer; Radical prostatectomy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; ETHNOLOGY; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; SEMINAL VESICLE; TIME SERIES ANALYSIS;

AGED; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; WALES;

EID: 33645678850     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091622     Document Type: Article

References (23)

1. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152:1831-1836.
2. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC: The use of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-114.
3. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update (erratum in JAMA 1997;278:118). JAMA 1997;277:1445-1451.
4. Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S, Conrad S, Henke R, Huland E, Huland H: Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol 1999;36:21-30.
5. Narayan P, Gajendran V, Taylor SP, Tewari A, Presti JC Jr, Leidich R, Lo R, Palmer K, Shinohara K, Spaulding JT: The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995;46:205-212.
6. Graefen M: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer - a multi-institutional update (in German). Aktuelle Urol 2004;35:377-378.
7. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD: Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58:843-848.
8. Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT, Montie JE, Pearson JD, Slezak JM, Zincke H: Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000;164:1591-1595.
9. Augustin H, Eggert T, Wenske S, Karakiewicz PI, Palisaar J, Daghofer F, Huland H, Graefen M: Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. J Urol 2004;171:177-181.
10. Graefen M, Augustin H, Karakiewicz PI, Hammerer PG, Haese A, Palisaar J, Blonski J, Fernandez S, Erbersdobler A, Huland H: Can predictive models for prostate cancer patients derived in the USA be utilized in European patients? A validation study of the Partin tables. Eur Urol 2003;43:6-11.
11. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997 (erratum in CA Cancer J Clin 1997;47:68). CA Cancer J Clin 1997;47:5-27.
12. Haas GP, Sakr WA: Epidemiology of prostate cancer. CA Cancer J Clin 1997;47:273-287.
13. 2001 C: Census 2001; in http://www.statistics. gov.uk/census/ (ed): http://www.statistics.gov.uk/census/
14. Bureau USC: State and county quick facts, 2000; in http://quickfacts. census.gov/qfd/
15. Gleason DF: Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-279.
16. Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H: Stage migration in clinically localized prostate cancer. Eur Urol 2000;38:74-78.
17. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC: Era-specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001;166:416-419.
18. Penson DF, Grossfeld GD, Li YP, Henning JM, Lubeck DP, Carroll PR: How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community-based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol 2002;167:1653-1658.
19. Eskicorapci SY, Karabulut E, Turkeri L, Baltaci S, Cal C, Toktas G, Akpinar H, Ozer G, Sozen S, Tokuc R, Lekili M, Soylu A, Albayrak S, Sahin H, Alpar R, Ozen H: Validation of 2001 Partin tables in Turkey: a multicenter study. Eur Urol 2005;47:185-189.
20. Epstein JI: Pathology of prostatic neoplasia, ed 8. Philadelphia, Saunders-Elsevier Science, 2002.
21. McNeal JE, Redwine EA, Freiha FS, Stamey TA: Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
22. Han M, Snow PB, Brandt JM, Partin AW: Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. Cancer 2001;91:1661-1666.
23. Potter SR, Miller MC, Mangold LA, Jones KA, Epstein JI, Veltri RW, Partin AW: Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. Urology 1999;54:791-795.